Delighted to share new article in @TheLancetOncol reviewing #UK post #Brexit #cancer drug approval pathways Thanks to amazing authors @ravindhi @sarah_blagden @AggarwalOnc @SullivanProf Thanks for input @PORTAL_Research @akesselheim @ImperialSandC

RT @prof_price: The time to act is now. Any further delay means more patients falling through the cracks and unnecessarily succumbing to th…

RT @Timothee_MD: How many patients with advanced or metastatic cancer respond to immunotherapy (checkpoint inhibitors)? Our new paper in t…

RT @NTFabiano: The irony

Very interesting letter from @oncology_bg (and co)about use of below sub-optimal control arms to adulate clinical outcomes in prostate cancer - is this becoming a more widespread problem? @JCO_ASCO

RT @DavidBenjaminMD: Is it time to re-classify urachal cancer as a GI rather than a GU malignancy? In @Nature_NPJ Precision Oncology, we s…

RT @kjmeetswrld: ✨Chuffed to have won the best presentation at @UUUIPS Winter Meeting. Was a great time hearing about different projects…

RT @BMJOncology: Happy new year! Looking forward to many important advances in the world of oncology.

RT @oncodaily: Subcutaneous nivolumab approved by @FDAOncologyacross all indications - @DrMarkLythgoe #Atezolizum…

@darioT_ @DTMichaeli @PORTAL_Research @Eddie_Cliff @oncology_bg @ajumathew_ @ArBayle @myESMO @kjmeetswrld Congrats @DTMichaeli - great work 👏

RT @darioT_: Findin' a best pricing approach 💲to #cancer drugs 💊💉 is still a challenge. Just after the presentation of the data at #ESMO24,…

@FDAOncology @oncodaily @mhadfield30 @DavidBenjaminMD @SullivanProf @AggarwalOnc @oncology_bg Our thoughts on the evolving #posology of #Immunecheckpointinhibitors in @trendscancer

RT @QUBCancerProf: WE DID IT! Our presentation to Health & Social Care Committee in Westminister in January has been fundamental to the gov…

RT @oncology_bg: NEW PAPER ALERT! In @JAMAOnc today: Summary/TLDR: 1. We found that the US government contribute…

RT @SullivanProf: Following Joint KCL ICP-WHO Cancer in Humanitarian settings meeting in Copenhagen in March and the Lancet manifesto on im…

RT @oncology_bg: Thank you. We have been advocating for this since 2018 but progress has been slow. What frustrat…

RT @bhmullish: Thanks to @gianluca1aniro for co-ordinating the international consensus statement on #microbiome testing in clinical practic…

RT @kjmeetswrld: Thrilled to have won an @LSEnews teaching award for my first course in the @LSEIRDept Global health: Science, Politics and…

@SuyogCancer @ByMadeleineA sounds a little bit like insulin like growth factor.......

@drtimrobinson @Nature @darioT_ @BreastDocUK @SuyogCancer @oncology_bg @BreastCancerNow @ElisaAgostinett @SullivanProf absolutely agree - the landscape is much (much) more complex now then when trial designed (also high use of palbociclib) but has profound implications for LMICs